PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26366090-7	2015	Moreover, cordycepin plus cisplatin and/or paclitaxel significantly induced cleavage of caspase-8, caspase-9, caspase-3, and poly ADP-ribose polymerase, and phosphorylation of c-Jun NH2-terminal kinase, extracellular signal-regulated kinase, p38, and p53 proteins in MA-10 cells.	Cisplatin	26-35	caspase 9	Mus musculus	99-108	
33646450-5	2021	Cisplatin-induced cell damages were evaluated by TUNEL assay and immunoblot analyses for p53, 14-3-3, Bax, Bcl2, cytochrome C, and activated caspases.	Cisplatin	0-9	caspase 9	Mus musculus	141-149	
33646450-7	2021	RESULTS: GW0742 suppressed cisplatin-induced apoptosis of mProx cells by reducing the activation of caspase-3 via attenuating the phosphorylation of p53 and 14-3-3, mitochondrial Bax accumulation, cytochrome C release from mitochondria to the cytosol and ensuing cytosolic caspase-9 activation.	Cisplatin	27-36	caspase 9	Mus musculus	273-282	
33365077-11	2021	In addition, the expression of survivin and XIAP was significantly downregulated, whereas the expression of caspase-3, caspase-7 and caspase-9 was significantly upregulated in tumor tissues from nude mice treated with matrine + cisplatin, compared with those treated with cisplatin, matrine or normal saline.	Cisplatin	228-237	caspase 9	Mus musculus	133-142	
33365077-12	2021	These findings suggested that the combination of matrine and cisplatin may promote tumor cell apoptosis in liver cancer by activating the caspase apoptosis pathway and suppressing the survivin-associated inhibition of caspase-9.	Cisplatin	61-70	caspase 9	Mus musculus	138-145	
33365077-12	2021	These findings suggested that the combination of matrine and cisplatin may promote tumor cell apoptosis in liver cancer by activating the caspase apoptosis pathway and suppressing the survivin-associated inhibition of caspase-9.	Cisplatin	61-70	caspase 9	Mus musculus	218-227	
30469321-5	2018	Western blotting showed that PDQ reversed the CDDP-induced (1) downregulation of Sirtuin-1 (Sirt-1), nuclear-related factor 2 (Nrf2), and Bcl-2, and (2) upregulation of NF-kappaB, Nox-4, Bax, caspase-9, and caspase-3.	Cisplatin	46-50	caspase 9	Mus musculus	192-201	
29312001-5	2017	Meanwhile, the cisplatin-increased renal thiobarbituric acid-reactive substances, caspase9, cleaved-caspase9, and cleaved-caspase3 were all diminished by QSYQ pretreatment.	Cisplatin	15-24	caspase 9	Mus musculus	82-90	
29312001-5	2017	Meanwhile, the cisplatin-increased renal thiobarbituric acid-reactive substances, caspase9, cleaved-caspase9, and cleaved-caspase3 were all diminished by QSYQ pretreatment.	Cisplatin	15-24	caspase 9	Mus musculus	100-108	
33045563-8	2020	Moreover, in the renal tissues of LIGHT KO mice, cisplatin-induced mitochondrion injury and the levels of the pro-apoptotic molecules Bax, Cytochrome C (Cyt C), cleaved caspase-3, and cleaved caspase-9 were dramatically increased; in contrast, the expression of anti-apoptotic molecule Bcl-2 was markedly reduced, compared to those in WT mice, suggesting that LIGHT deficiency accelerated cisplatin-induced mitochondrial apoptosis of renal tubular cells in these mice.	Cisplatin	49-58	caspase 9	Mus musculus	192-201	
32543135-14	2020	Compared with the control group, in the three groups that treated with DDP, the formation of clones and the expression of proliferation marker proteins Ki67 and PCNA were reduce ( P<0.01), while the rate of apoptosis and the expression of apoptosis marker proteins Caspase-3 and Caspase-9 were increased ( P<0.01).	Cisplatin	71-74	caspase 9	Mus musculus	279-288	
26438401-9	2016	We found that KCa3.1 blockade attenuated cytochrome c release and the increase in the intrinsic apoptotic mediators Bax, Bak, and caspase-9 after cisplatin treatment.	Cisplatin	146-155	caspase 9	Mus musculus	130-139	
23678002-3	2013	Here, we demonstrate that treatment with CDDP resulted in down-regulation of c-Jun expression via caspase-9-dependent cleavage of c-Jun at Asp-65 and MEKK1-mediated ubiquitylation and degradation of c-Jun in CDDP-sensitive cancer cells.	Cisplatin	41-45	caspase 9	Mus musculus	98-107	
23678002-3	2013	Here, we demonstrate that treatment with CDDP resulted in down-regulation of c-Jun expression via caspase-9-dependent cleavage of c-Jun at Asp-65 and MEKK1-mediated ubiquitylation and degradation of c-Jun in CDDP-sensitive cancer cells.	Cisplatin	208-212	caspase 9	Mus musculus	98-107	
22681485-10	2012	The expression of Bax, caspase-9, and caspase-3 in cisplatin-treated cells were also decreased by PC treatment.	Cisplatin	51-60	caspase 9	Mus musculus	23-32	
12746256-5	2003	In contrast to p21(+/+) MPTC, cisplatin activated caspase-9 but not caspase-8 in p21(-/-) MPTC before caspase-3 activation.	Cisplatin	30-39	caspase 9	Mus musculus	50-59	
12746256-9	2003	We conclude that 1) in the presence of p21, cisplatin activates caspase-3 through a mechanism independent of caspase-8 or caspase-9; 2) in the absence of p21, caspase-9 activation precedes caspase-3 activation; 3) the lack of p21 accelerates caspase-3 activation and cisplatin-induced MPTC apoptosis; and 4) MPTC apoptosis is caspase independent in the presence of p21 but partially dependent on caspases in the absence of p21.	Cisplatin	44-53	caspase 9	Mus musculus	159-168